Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.53%, which has investors questioning if this is right time to buy.

Drugs that both activate and block the GIP receptor reduce weight through different brain mechanisms, offering a new ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

(Reuters) -The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Navigating ineffective weight management treatment is a sensitive process that requires acknowledgement of bias from both ...